@misc{10481/63633,
year = {2020},
month = {8},
url = {http://hdl.handle.net/10481/63633},
abstract = {The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the
clinical symptoms mostly have been characterized, the scientifc community still doesn´t know how SARS-CoV-2 successfully reaches
and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fuid (CSF) and in frontal lobe sections from postmortem examination has confrmed the presence of the virus in neural tissue.
This fnding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases.
Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin,
which may favorably modulate the immune response and neuroinfammation caused by SARS-CoV-2. However, clinical trials elucidating the efcacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.},
publisher = {SPRINGER/PLENUM PUBLISHERS},
keywords = {SARS-CoV-2},
keywords = {Melatonin},
keywords = {COVID-19},
keywords = {Central nervous system},
keywords = {Neuroinvasion},
keywords = {Neuroprotection},
title = {Coronavirus Disease 2019 (COVID‑19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?},
doi = {10.1007/s10571-020-00938-8},
author = {Romero, Alejandro and Escames Rosa, Germaine},
}